India's Stance On IPRs, Pharma in FTA Will Fosters Growth Of Generic Drug Sector: GTRI
ABP NewsIndia's position on intellectual property rights and pharmaceutical issues in proposed trade agreements strikes a balance between fostering innovation and addressing public health needs. By resisting pressures from developed nations regarding concepts like 'data exclusivity' and 'patent linkage' in free trade agreements, India facilitates greater market access for generic drug manufacturers, leading to a significant reduction in the cost of life-saving medications. Proposed FTA terms from developed nations often encompass TRIPs-plus provisions, encompassing aspects such as data exclusivity, patent term extensions, patent evergreening, expanded patentability criteria, and patent linkage. "India scrutinises patent applications rigorously to avoid evergreening, where minor modifications to existing patents extend monopolies, a practice not explicitly addressed by TRIPs but requiring new inventions for patentability," he said.